On September 2, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported that Mani Mohindru, Ph.D. will participate in two upcoming conferences.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the company’s participation are as follows:
8th Annual RAS-Targeted Drug Development Summit
Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesday, September 8 at 9:00 AM ET
H.C. Wainwright 28th Annual Global Investment Conference
Fireside Chat; Monday, September 14 at 10:00 AM ET
After the conclusions of these events, interested parties can access slides by visiting the "Events" section of the Cardiff Oncology website. In addition, for the H.C. Wainwright conference, interested parties can register for and access the live webcast for the conference by visiting the "Events" section of the Cardiff Oncology website. That webcast replay will be available after the conclusion of the presentation.
(Press release, Cardiff Oncology, SEP 2, 2026, View Source [SID1234670567])